Background: Pneumonia is a major cause of morbidity and mortality of children. Zinc is known to play a central role in the immune system. The deficiency of zinc increased susceptibility to infectious diseases.
Results: Six randomized DBPC trials including 2216 patients with severe pneumonia were eligible. The results suggested that zinc given as an adjunct therapy to the treatment of severe pneumonia had no significant improvement of treatment failure (RR 5 0.97, P 5 .71) and change of antibiotic therapy (RR 5 1.09, P 5 .52). We also found a favorable trend for clinical deterioration of severe pneumonia but with no statistical significance (RR 5 0.88, P 5 .55). Zinc produced a significant reduction in mortality caused by severe pneumonia (RR 5 0.43, P 5 .01).
Conclusions: Zinc given as an adjunct to the treatment of severe pneumonia is effective in reducing the mortality of severe pneumonia, and has no significant effects on treatment failure and change of antibiotic therapy.
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| IN TRO DUCT IO N
Pneumonia is a major cause of morbidity and mortality of children, especially in developing countries, and responsible for about 18% deaths in children younger than 5 years. 1 Zinc is known to play a central role in the immune system, and affects multiple aspects of the immune system including innate and adaptive immune system. 2 The deficiency of zinc increased susceptibility to infectious diseases. Many studies have demonstrated the benefits of zinc supplementation on infectious diseases in human populations, such as diarrhea, acute lower respiratory tract infections, measles and recurrent boils. Some studies found zinc could reduce the incidence and duration of diarrhea, 3, 4 and also reduced the frequency and severity of diarrhea and acute lower respiratory tract infections in children. 5, 6 However, the therapeutic effect of zinc on severe pneumonia yielded mixed results. Four randomized controlled trials found that zinc did not affect treatment failure, 7-10 but another study conducted in children aged 2-35 month found zinc supplement reduced the risk of treatment failure. 11 Moreover, Semp ertegui found zinc had no effect on the mortality and clinical deterioration, 7 but Srinivasan found zinc reduced the mortality caused by severe pneumonia. 12 The objective of our meta-analysis was to evaluate the therapeutic effect of zinc on treatment failure, change of antibiotics, mortality and clinical deterioration in patients with severe pneumonia by screening the randomized double-blind and placebo-controlled (DBPC) trials.
| MET HOD S

| Search strategy
A literature search was performed to identify all clinical trials that addressed the clinical efficacy of zinc in patients with severe pneumonia. The PubMed, Embase, MEDLINE TM and the Cochrane Central Register of Controlled Trials were searched to identify all DBPC trials published up to October 2015. Terms used in the search were 'severe pneumonia', 'severe case pneumonia', 'serious pneumonia', 'grave pneumonia', 'pneumonia gravis', 'zinc', 'zn'. The search was limited to 'English language' and 'humans'. The data search was further augmented by scanning the references of identified articles or reviews and clinical symposia abstracts and contacting with authors of included studies inquiring about potentially eligible studies that we might have missed.
| Study selection
The eligibility criteria of included studies were: (a) studies were randomized, DBPC trials; (b) studies were limited to English language and humans; (c) participants were patients with severe pneumonia; (d) studies reporting at least one following clinical outcomes: treatment failure, change in antibiotics, mortality, clinical deterioration; (e) the outcomes of studies were expressed with mean and standard deviation. Relevant literatures were identified according to the stated criteria strictly, and disagreements were resolved by consensus. The Jadad scale was used to access the methodological quality of trials and selected those with no less than 3 points. Studies with insufficient data and no replies from authors after 6 weeks via email were excluded.
| Data extraction and risk of bias assessment
The main outcome measures were the treatment failure, change in antibiotics, mortality and clinical deterioration.
Insufficient data were requested by contacting the authors. Characteristics of the included studies were summarized in Table 1 . The methodological quality of trials was accessed using the Jadad scale, which is based on the 3 following subscales: randomization (2, 1 or 0), blinding (2, 1 or 0) and dropouts/withdrawals (1 or 0). Risk of bias for each included study was assessed following the guidelines of the Cochrane Collaboration. 13 Publication bias was evaluated using a funnel plot. Selection bias (methods of random sequence generation and allocation concealment), performance bias (methods of blinding) and detection bias were assessed.
| Statistical analysis
Review Manager 5. value > 50%, a random effects model was used to calculate the standardized mean difference; otherwise, a fixed effects model was chosen to calculate risk ratio (RR) and 95% confidence intervals. Sensitivity analyses were conducted to determine the impact of excluding studies with lower Jadad scores and dropout rate more than 15%. The weighted averages of treatment effects were compared using the two-tailed Mann-Whitney U-test. P values < .05 were considered statistically significance.
| RES UL TS
| Characteristics of included studies
The initial literature search identified 120 published articles, of which 12 were potentially relevant trials on zinc in severe pneumonia. Six randomized DBPC trials were eligible for our meta-analysis by reading the full texts in detail ( Figure 1 ). 2216 patients with severe pneumonia were involved. Zinc was given to 1112 patients and placebo to 1104 patients. Age range was 2-60 months, and sample size ranged from 117 to 598 subjects. High variability was observed in cumulative dose of zinc ranged from 70 to 280 mg, and one study did not mention the cumulative dose. 7 Duration of treatment varied which ranged from 7 to 14 days, and duration of the study reported by Semp ertegui was designed until hospital discharge (Table 1 ). All included trials mentioned explicitly the definition of severe pneumonia and treatment failure and standard antibiotic treatments based on guidelines. 
| Methodological quality of included studies
We discovered reasonable symmetry in the funnel plot, and the plot should approximately resemble an inverted funnel when without bias (Figure 2 ). According to the Jadad scale score, 4 studies had a score of 5/5 and 2 studies 4/5. The allocation concealment was clearly adequate (category A) in all eligible studies. All studies reported dropouts or withdrawals (Table 1) . But only one trial conducted intention-to treat analysis to assess the influence of dropouts/ withdrawals. 
| Treatment failure
Five studies assessed the efficacy of zinc by using treatment failure including change of antibiotics therapy, mortality and clinical deterioration. Statistical evaluation of the outcome did not identify heterogeneity between studies (I 2 5 0%, P 5 .56), thus a fixed effects model was used to calculate the RR and 95% confidence intervals. 1822 patients with severe pneumonia were involved. Zinc was given to 915 patients and placebo to 907 patients. The treatment failure number of zinc had a total of 240 patients in these 5 studies, and placebo had 245 patients. The risk of treatment failure found in our meta-analysis was RR 0.97 (95% confidence interval, 0.84 to 1.13), and no significant improvement of treatment failure was found in these 5 studies (Z 5 0.38, P 5 .71) ( Figure 3A) . Subgroup analysis was performed to evaluate the effect of zinc on treatment failure with treatment duration more than 7 days. Four trials were included in the analysis. The risk of treatment failure was RR 0.99 (95% confidence interval, 0.85 to 1.15), and no significant change was found (Z 5 0.17, P 5 .86) ( Figure 3B ).
| Change of antibiotic therapy
All participants were given standard antimicrobial regimens except zinc. Antibiotic therapy was changed and another appropriate therapy was started when clinical deterioration occurred. In our meta-analysis, 3 eligible trials assessed the efficacy of zinc on the change of antibiotic therapy. 1067 patients were involved. Zinc was given to 541 patients and FIGU RE 1 Flow diagram showing the trial selection process for the present meta-analysis FIGU RE 2 Funnel plot for publication bias detection for treatment failure placebo to 526 patients. Overall number of change of antibiotics was 192, and zinc had 102 while placebo 90. The risk of change of antibiotics was RR 1.09 (95% confidence interval, 0.84 to 1.40), and no significant difference was found in these 3 studies (Z 5 0.64, P 5 .52), indicating that zinc had no effect on change of antibiotics of severe pneumonia (Figure 4A) . Subgroup analysis was performed to evaluate the effect of zinc on change antibiotics with treatment duration more than 7 days. Two trials were included in the analysis. The risk of change of antibiotics was RR 1.16 (95% confidence interval, 0.88 to 1.52), and no statistical significance was found (Z 5 1.02, P 5 .31) ( Figure 4B ).
| Mortality caused by severe pneumonia
Three eligible trials assessed the efficacy of zinc on the mortality caused by severe pneumonia. 1318 patients were involved. Zinc was given to 658 patients and placebo to 660 patients. The total death was 40, and zinc had 12 patients while placebo 28 patients. The risk of mortality was RR 0.43 (95% confidence interval, 0.22 to 0.83) and a significant difference was found in these 3 studies (Z 5 2.51, P 5 .01), indicating that a significant reduction in mortality caused by severe pneumonia among patients receiving zinc compared with those receiving placebo ( Figure 5A ). 
|
Subgroup analysis was performed to evaluate the effect of zinc with treatment duration more than 7 days. Two trials were included in the analysis. The risk of mortality increased from 0.43 to 0.72, and the improved effect of zinc on mortality disappeared (Z 5 0.57, P 5 .57) ( Figure 5B ).
| Clinical deterioration of severe pneumonia
The efficacy of zinc on clinical deterioration of severe pneumonia was assessed by 2 eligible trials. 966 participants involved these 2 studies. 482 patients were given zinc while 484 given placebo. The total number of clinical deterioration was 75, and zinc had 35 patients while placebo 40 patients. The risk of clinical deterioration was RR 0.88 (95% confidence interval, 0.58 to 1.33), and no significant difference was found in these 3 studies (Z 5 0.60, P 5 .55), indicating that zinc had no effect on clinical deterioration (Figure 6 ).
| Sensitivity analysis
A sensitivity analysis was restricted to studies classified as 5A, the calculated RR retained no statistical significance of efficacy of zinc on treatment failure and change of antibiotics (RR 5 0.99, P 5 .86; RR 5 1.16, P 5 .31). However, the pooled RR of mortality changed from 0.43 to 0.72, and the efficacy of zinc on mortality was obviously decreased (P 5 .01 vs P 5 .57).
A sensitivity analysis was also performed to determine the effect of excluding a study with a dropout rate more than 15%, we found the effect of zinc on treatment failure remained no significance (RR 5 0.96, P 5 .64) (Figure 7 ).
| DI S CUS S I ON
Zinc is known to play a central role in the immune system, and zinc-deficient persons experience increased susceptibility to a variety of pathogens. The mechanisms by which zinc changes human susceptibility to pathogens include the regulation of proinflammatory cytokine secretion, 14 lymphocyte proliferation, 15 T lymphocyte function 16 and preservation of the integrity of respiratory epithelial cells. 17 Many studies suggested zinc supplementation could reduce the mortality and morbidity due to acute lower respiratory infections (ALRIs). Zinc supplementation does not have an effect on total mortality, diarrhea-related mortality, pneumonia-related mortality, malaria-related mortality or other causes of mortality. 19 However, the effect of zinc supplementation in reducing treatment failure, change of antibiotic therapy and clinical deterioration and mortality of severe pneumonia has not been confirmed by meta-analysis. The results of the present meta-analysis of randomized DBPC trials indicated that zinc given as an adjunct to the treatment of severe pneumonia demonstrated a significant reduction of mortality caused by severe pneumonia. However, there was no significant improvement of treatment failure and change of antibiotic therapy. We also found a favorable trend of clinical deterioration by severe pneumonia but with no statistical significance. This result which zinc reduced the mortality of severe pneumonia is not surprising because zinc is known to regulate the immune response such as increasing phagocytosis and preservation of T cell function and intracellular killing. However, these results were derived from very few cases and small number of trials. More clinical trials are needed to further confirm the treatment effect of zinc.
Subgroup analyses performed to evaluate the effects of zinc with treatment duration more than 7 days showed a similar result in treatment failure and change of antibiotic therapy with the obtained result in the analysis of all studies. However, the effect of zinc on mortality in subgroup was opposite with the obtained result in the analysis of all 3 studies, we thought this analyzed result was closely related with the great weight of the trail with treatment duration less than or equal to 7 days. Therefore, a long-term prospective study aimed at examining optimal treatment duration for the best long-lasting effects of zinc is needed.
The methodological quality of these included trials in this meta-analysis was mainly moderate or appropriately good according to the Jadad scale. However, a sensitivity analysis performed to evaluate the effect of excluding one trial classified as 4A on mortality produced results that were not consistent with those obtained in the analysis of all 3 studies. The reason resulted in the divergence we thought associated with this trial having a great weight.
There are several limitations that should be considered when interpreting these results. First, publication bias is an important defect of meta-analysis and its effects can never be eliminated. In the present meta-analysis, we discovered no evidence of publication bias through funnel plot analysis, though only published literatures reported. So publication bias could be considered unlikely to influence our pooled estimates. Second, insufficient data and the paucity of studies evaluating variables may impair and confine the results in our meta-analysis. Third, only one trial conducted intentionto treat analysis to assess the influence of dropouts/withdrawals in this meta-analysis, so absence of conducting intention-to-treat analysis should not be neglected.
| CONC LUS I ON S
The present meta-analysis of randomized DBPC trials implies that zinc given as an adjunct to the treatment of severe pneumonia is effective in reducing mortality of severe pneumonia, and has no significant effects on treatment failure and change of antibiotic therapy. There was a tendency toward clinical deterioration but with no statistical significance. The evidence-based recommendations of optimal treatment duration of zinc supplementation need further investigation.
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